Due　to　lack　of　systematic　reviews,　BRCA,　DNA　Repair　Associated　(BRCA)　mutations　in　the　Chinese　population　are　not　completely　understood.　The　following　study　investigates　the　prevalence　and　type　of　BRCA　mutations　in　Chinese　patients　with　high　hereditary　risk　of　breast　cancer　(BC).　Patients　Drwere　recruited　from　14　cities　between　October　2015　and　February　2016,　and　were　selected　based　on　family　and　personal　medical　history.　BRCA　mutations　were　analyzed　by　collecting　blood　samples　from　all　participants.　437　BC　patients　were　included.　A　total　of　seventy-six　(17.4%)　mutation　carriers　were　identified　with　no　geographic　difference.　The　mutation　rate　in　the　early-onset　BC　patients　was　lower　compared　to　family　history　of　breast/ovarian　cancer　(OC),　bilateral　BC,　male　BC,　BC&OC　or　meeting　＞=　2　criteria　(9.2　vs.　21.7,　24.0,　22.2,　16.7　and　24.3%,　respectively,　P=0.007).　A　total　of　61　mutation　sites　were　identified　(BRCA1　32,　BRCA2　29)　including　47.5%　novel　sites　and　extra　10　variants　of　uncertain　significance.　A　total　of　five　sites　were　repeated　in　more　than　one　unrelated　patient.　A　total　of　11　sites　were　associated　with　hereditary　breast　and　ovarian　cancer　syndrome,　two　of　which　were　confirmed　by　family　pedigrees.　Compared　with　BRCA-patients,　patients　with　BRCA1　mutation　tended　to　be　triple-negative　BC　(P＜0.001),　whereas　patients　with　BRCA2　mutation　were　more　likely　to　be　hormone　receptor　positive　BC　(P=0.02).　The　present　study　provides　a　general　BRCA　mutation　profile　in　the　Chinese　population.　The　prevalence　of　BRCA　mutation　in　BC　patients　with　high　hereditary　risk　is　lower　compared　with　Western　populations.　Chinese　mutation　type　is　different　with　Western　people,　without　obvious　founder　mutation.